Breaking News: UbriGene Biosciences Inc Secures $200 Million for Revolutionary ATMP Commercialization Services

UbriGene Biosciences Inc. is thrilled to announce that it has successfully raised $200 million in its latest funding round, a pivotal milestone that will further propel its mission to bridge the gap from advanced therapy medicinal products (ATMPs) concept to commercialization. As a leading Contract Development and Manufacturing Organization (+CDMO), UbriGene specializes in developing innovative cell therapy products, including CAR-T, TCR-T, NK cells, and diverse viral vectors like AAV, LVV, RVV, and oncolytic viruses. The fresh capital will be strategically utilized to expand our Centers of Excellence across North America and the Asia Pacific, as well as to boost our capabilities in GMP clean room suites, ensuring we remain at the forefront of global cell and gene therapy, vaccine, and RNA product development. The funding will also enhance our manufacturing, quality control testing, and regulatory filing support services, accelerating the therapeutic development process from bench to bedside. With this infusion, UbriGene aims to strengthen its position as an essential player in the rapidly evolving biotech landscape, driving innovation and improving patient outcomes through cutting-edge therapies. We are excited about the future and committed to utilizing this funding to provide transformative solutions that meet the needs of our partners and the patients we ultimately serve.